Vaxart Inc (NASDAQ:VXRT)’s share price dropped 21.6% on Monday . The company traded as low as $1.46 and last traded at $1.49. Approximately 1,504,871 shares traded hands during mid-day trading, an increase of 140% from the average daily volume of 626,058 shares. The stock had previously closed at $1.90.

The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.96 and a current ratio of 1.96.

Vaxart (NASDAQ:VXRT) last issued its earnings results on Wednesday, February 6th. The biotechnology company reported ($0.66) earnings per share for the quarter. The business had revenue of $1.77 million during the quarter. Vaxart had a negative net margin of 441.12% and a negative return on equity of 82.05%.

A hedge fund recently raised its stake in Vaxart stock. Renaissance Technologies LLC grew its holdings in Vaxart Inc (NASDAQ:VXRT) by 9.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 233,862 shares of the biotechnology company’s stock after purchasing an additional 19,800 shares during the period. Renaissance Technologies LLC owned about 3.28% of Vaxart worth $667,000 as of its most recent SEC filing. Institutional investors own 5.88% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Vaxart (VXRT) Shares Down 21.6%” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at

About Vaxart (NASDAQ:VXRT)

Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.

See Also: Is the QQQ ETF safe?

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with's FREE daily email newsletter.